Business Context and Reporting Period
This Form 8-K Current Report was filed by Chemomab Therapeutics Ltd. on June 1, 2022. The company is an emerging growth company incorporated in Israel, with its principal executive offices in Tel Aviv. Its American Depositary Shares trade on the Nasdaq Capital Market under the symbol CMMB.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes rather than financial performance.
Material Changes
The primary material change reported is the departure of Joel Maryles from the Board of Directors. Mr. Maryles notified the company on May 31, 2022, that he will not stand for re-election at the 2022 Annual General Meeting scheduled for June 7, 2022. Consequently, his term as a Class I director will expire at that meeting.
Management Commentary and Risks
Management explicitly stated that Mr. Maryles' departure is not due to any disagreement with the Company, its management, the Board, or any committee thereof. Furthermore, the departure is unrelated to any matter concerning the Company's operations, policies, or practices. No other risks, contingencies, or unusual items were disclosed in this filing.
Investor Verification Checklist
- Verify the outcome of the 2022 Annual General Meeting held on June 7, 2022, regarding the election of directors.
- Confirm whether a replacement director was nominated to fill the vacancy left by Mr. Maryles.
- Review subsequent filings for any updates on the Board composition or strategic direction following this departure.